Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Large Decrease in Short Interest

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 4,540,000 shares, a decline of 9.9% from the January 15th total of 5,040,000 shares. Currently, 18.5% of the company’s shares are sold short. Based on an average daily volume of 429,700 shares, the days-to-cover ratio is presently 10.6 days.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $18.05 on Tuesday. The firm has a market capitalization of $488.97 million, a PE ratio of -8.13 and a beta of 2.62. The stock’s 50 day moving average price is $17.00 and its 200 day moving average price is $18.89. Arcturus Therapeutics has a one year low of $14.30 and a one year high of $45.00.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ARCT. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. BTIG Research assumed coverage on shares of Arcturus Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $41.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research note on Friday. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Arcturus Therapeutics presently has an average rating of “Buy” and a consensus price target of $65.00.

Hedge Funds Weigh In On Arcturus Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its stake in Arcturus Therapeutics by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock valued at $1,647,000 after acquiring an additional 742 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Arcturus Therapeutics by 10.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 846 shares during the period. Ameriprise Financial Inc. lifted its stake in Arcturus Therapeutics by 5.0% in the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 883 shares during the last quarter. Virtus ETF Advisers LLC boosted its holdings in shares of Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 1,132 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Arcturus Therapeutics by 7.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company’s stock worth $323,000 after acquiring an additional 1,279 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.